文献速递主动脉疾病

药物管理的B型壁内血肿的自然病史与长期结局

Natural history and long-term outcomes of medically managed Type B intramural hematoma.
PubMed 文献 · J Vasc Surg · 2024-06-20

单中心回顾1995年1月至2022年12月药物管理的B型壁内血肿患者,排除即刻手术或血管内干预者。92例中位年龄77岁,中位随访55个月,1年和5年总生存率分别为85.8%和61.9%。随访期间20.7%需干预,第2组(就诊时合并动脉瘤或夹层)干预率42.3%高于第1组(孤立性壁内血肿)12.3%(P = .001)。就诊时壁内血肿厚度>7.2 mm与进展和干预风险增加相关。

要点

  • 药物管理的B型壁内血肿患者中,随访期间约20.7%需干预,第2组干预率42.3%高于第1组12.3%(P = .001)。
  • 就诊时壁内血肿厚度>7.2 mm与进展风险增加相关(比值比3.3,95%CI 1.2-11.1,P = .03)。
  • 就诊时壁内血肿厚度>7.2 mm与干预风险增加相关(比值比5.5,95%CI 1.3-36.9,P = .03)。

核心结论

  • 尽管许多药物管理的B型壁内血肿患者稳定或消退,但进展或需要干预可发生于高达40%的病例。
  • 进展与就诊时存在动脉瘤、夹层及壁内血肿厚度相关。
  • 由于晚期干预会发生,尤其对高风险患者,长期随访是强制性的。

研究设计与样本

  • 单中心回顾性研究,回顾1995年1月至2022年12月期间药物管理的B型壁内血肿患者,排除立即接受外科或血管内干预者。
  • 共104例B型壁内血肿患者,其中92例接受药物管理;中位年龄77岁,女性45例(48.9%)。
  • 患者分为两组:第1组为孤立性壁内血肿(66例),第2组为就诊时壁内血肿合并动脉瘤或夹层(26例)。

主要发现

  • 合并症包括高血压(83.7%)、高胆固醇血症(44.6%)和活跃吸烟(47.8%);平均血管外科学会合并症评分为6.3。
  • 就诊时平均壁内血肿厚度为8.9 mm,平均主动脉直径为38.3 mm;中位随访55个月。
  • 1年和5年总生存率分别为85.8%和61.9%。
  • 随访期间19例(20.7%)需要干预,第2组更常见(第1组8/66,12.3% vs 第2组11/26,42.3%;P = .001)。
  • 第1组1年和5年免于干预率分别为93.5%和87.5%,第2组分别为62.7%和51.1%(P < .001)。

临床怎么用

  • 作者认为,尽管许多药物管理的B型壁内血肿患者稳定或消退,但进展或需要干预可发生于高达40%的病例。
  • 作者认为,进展与就诊时存在动脉瘤、夹层及壁内血肿厚度相关。
  • 作者建议,由于晚期干预会发生,尤其对高风险患者,长期随访是强制性的。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type B intramural hematoma (IMH) is often managed medically, yet may progress to dissection, aneurysmal dilation, or rupture. The aim of this study was to report the natural history of medically managed Type B IMH, and factors associated with progression. METHODS: We reviewed patients with medically managed Type B IMH between January 1995 to December 2022 at a single center. Any patients with immediate surgical or endovascular intervention were excluded. Demographic profiles, comorbidities, imaging, and follow-up details were reviewed. Patients were divided into two groups: Group 1 had isolated IMH, and Group 2 had IMH along with aneurysm or dissection at the time of presentation. On follow-up, progression was defined as degeneration to aneurysm/dissection or increase in the thickness of IMH in Group 1. In Group 2, progression was an increase in the size of aneurysm or development of new dissection. RESULTS: Of 104 patients with Type B IMH during the study period, 92 were medically managed. The median age was 77 years, and 45 (48.9%) were females. Comorbidities included hypertension (83.7%), hypercholesterolemia (44.6%), and active smoking (47.8%). Mean Society for Vascular Surger comorbidity score was 6.3. Mean IMH thickness and aortic diameter at presentation were 8.9 mm and 38.3 mm, respectively. Median follow-up was 55 months. Overall survival at 1 year and 5 years was 85.8% and 61.9%, respectively. During follow-up, 19 patients (20.7%) required intervention, more common in Group 2 (Group 1, 8/66; 12.3% vs Group 2, 11/26; 42.3%; P = .001). This resulted in higher freedom from intervention in Group 1 at 1 year (93.5% vs 62.7%) and 5 years (87.5% vs 51.1%; P < .001). Indication for intervention was dissection (n = 4), aneurysm (n = 12), and progression of IMH (n = 3). In Group 1, progression was seen in 25 (37.9%), three (4.5%) remained stable, 29 (43.9%) had complete resolution of IMH, and nine patients were lost to follow-up. In Group 2, 11 patients (42.3%) had progression, seven (26.9%) remained stable, and eight were lost to follow-up. IMH thickness at presentation >7.2 mm is associated with both increased odds of progression (odds ratio, 3.3; 95% confidence interval, 1.2-11.1; P = .03) and intervention (odds ratio, 5.5; 95% confidence interval, 1.3-36.9; P = .03) during the follow-up. CONCLUSIONS: Although many patients with Type B IMH managed medically stabilize or regress, progression or need for intervention can occur in up to 40% of cases. This is associated with the presence of aneurysm, dissection, and IMH thickness. Long-term follow-up is mandatory as late interventions occur, particularly for higher risk patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Vaddavalli VV, Wilkins PB, Schaller MS, et al. Natural history and long-term outcomes of medically managed Type B intramural hematoma. J Vasc Surg. 2024. PMID: 38904581. doi:10.1016/j.jvs.2024.04.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。